Stockscreener 앱 받기
68.36
0.90%
-0.62
시간 외 거래:
68.38
0.02
+0.03%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Nektar Therapeutics MS Collaboration Adds New Angle To Volatile Stock Story - simplywall.st
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet - Finviz
Nektar Therapeutics (NKTR) Price Target Increased by 13.48% to 132.45 - Nasdaq
Wall Street experts predict that Nektar (NKTR) may climb by 89.8%: Consider this information before making an investment decision - Bitget
Nektar Therapeutics to Participate in Two Investor Conferences in March - Barchart.com
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 75.19 USD By Investing.com - Investing.com India
Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at B. Riley Financial - Defense World
Nektar Therapeutics (NKTR) Receives Positive Analyst Rating Upgr - GuruFocus
B. Riley Securities Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration - simplywall.st
Nektar Therapeutics stock hits 52-week high at 75.19 USD - Investing.com
B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating - marketscreener.com
Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial - Medical Dialogues
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
What is Nektar Therapeutics’s valuation compared to sectorJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru
Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR - MarketBeat
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - StreetInsider
Nektar Therapeutics stock pops on $300M equity offering - MSN
UCSF, Nektar team to test potential of antibody therapy for MS - Multiple Sclerosis News Today
Which Is a Better Investment, Liquidia Corporation or Nektar Therapeutics Stock? - AAII.com
Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Nektar Therapeutics Stock? - AAII
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
Nektar Therapeutics and UCSF explore TNFR2 agonism in MS - bioworld.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month HighShould You Buy? - MarketBeat
45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP - MarketBeat
Nektar Therapeutics Announces Research Collaboration with University of California, San Francisco - marketscreener.com
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”GEN - GEN - Genetic Engineering and Biotechnology News
Assessing Nektar Therapeutics (NKTR) Valuation After Positive REZOLVE AD Data And Major Equity Financing - Sahm
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - BioSpace
Nektar Therapeutics Announces Research Collaboration With Ucsf And Dr. Stephen Hauser For Nktr-0165 - TradingView
Breakthrough Prize MS pioneer joins Nektar to test new antibody - Stock Titan
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight (2026-02-16) - Seeking Alpha
NKTR stock soars after Nektar reports positive atopic dermatitis trial results - MSN
Nektar Therapeutics prices $400M stock offering - MSN
Nektar Therapeutics closes $460 million public offering By Investing.com - Investing.com Australia
Nektar Therapeutics Secures Major Funding as Shares Rally - AD HOC NEWS
Nektar Therapeutics Announces Closing of $460 Million Public Off - GuruFocus
Nektar Therapeutics closes $460 million public offering - Investing.com
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - Sahm
Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
Nektar Stock: $400M Dilution And A Make-Or-Break Phase 3 - Trefis
Nektar Therapeutics Prices Upsized Public Equity Offering - TipRanks
Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria
Nektar Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView
Why Nektar Therapeutics (NKTR) Is Up 102.2% After Strong REZOLVE-AD Data And $400 Million Raise - Yahoo Finance
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals
Nektar Therapeutics stock falls after $400 million public offering - Investing.com
Nektar Therapeutics stock falls after $400 million public offering By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month HighHere's Why - MarketBeat
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st
HC Wainwright Expects Lower Earnings for Nektar Therapeutics - MarketBeat
2.90%
2.73%
자본화:
|
볼륨(24시간):